- Home
- RSLS vs SNPX Comparison
RSLS vs SNPX Comparison
Compare RSLS & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- SNPX
- Stock Information
- Founded
- RSLS 2002
- SNPX 2012
- Country
- RSLS United States
- SNPX United States
- Employees
- RSLS N/A
- SNPX N/A
- Industry
- RSLS Medical/Dental Instruments
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- RSLS Health Care
- SNPX Health Care
- Exchange
- RSLS Nasdaq
- SNPX Nasdaq
- Market Cap
- RSLS 3.1M
- SNPX 3.7M
- IPO Year
- RSLS 2007
- SNPX N/A
- Fundamental
- Price
- RSLS $4.38
- SNPX $3.07
- Analyst Decision
- RSLS Hold
- SNPX Strong Buy
- Analyst Count
- RSLS 1
- SNPX 1
- Target Price
- RSLS N/A
- SNPX $14.00
- AVG Volume (30 Days)
- RSLS 30.3K
- SNPX 18.6K
- Earning Date
- RSLS 11-14-2024
- SNPX 11-12-2024
- Dividend Yield
- RSLS N/A
- SNPX N/A
- EPS Growth
- RSLS N/A
- SNPX N/A
- EPS
- RSLS N/A
- SNPX N/A
- Revenue
- RSLS $8,183,000.00
- SNPX N/A
- Revenue This Year
- RSLS $17.47
- SNPX N/A
- Revenue Next Year
- RSLS $20.00
- SNPX N/A
- P/E Ratio
- RSLS N/A
- SNPX N/A
- Revenue Growth
- RSLS N/A
- SNPX N/A
- 52 Week Low
- RSLS $4.09
- SNPX $2.32
- 52 Week High
- RSLS $29.00
- SNPX $8.78
- Technical
- Relative Strength Index (RSI)
- RSLS 32.94
- SNPX 57.58
- Support Level
- RSLS $4.09
- SNPX $2.52
- Resistance Level
- RSLS $4.80
- SNPX $2.80
- Average True Range (ATR)
- RSLS 0.40
- SNPX 0.21
- MACD
- RSLS -0.06
- SNPX 0.00
- Stochastic Oscillator
- RSLS 18.24
- SNPX 87.30
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.